Welcome to Maternal Genomics

Maternal Genomics is devoted to offering the latest state-of-the-art prenatal screening technologies to all pregnant women to ensure that they are well-informed about their pregnancies.

Get the most recommended method for non-invasive prenatal testing!*

Led by a clinical geneticist, we offer the Verifi® test to all Canadians, which provides the most accurate noninvasive test on the market for genetic chromosomal abnormalities, at no risk to the pregnancy.

We provide educational materials and sessions led by trained genetic counsellors to help you understand the test and guide you along the way.

 *Genetics in Medicine (2022), 1-12

Maternal Genomics Calgary

215-971 64 Ave NE

Calgary, AB T2E 7Z4

Canada

Phone: +1 (587) 885 3158

Fax: +1 (587) 441-8380


Email: clinic@magiccalgary.ca

STEP 1

Make an appointment as early as 10 weeks into your pregnancy.
 

STEP 2

Get your blood test and see a genetic counsellor. It only takes one tube of blood!

STEP 3

See your genetic counsellor in 7 days or less for results.
 

When you pick up your results, we will have a genetic counsellor here to help you understand your results and answer any questions that you may have about them.

Advantages of the Maternal Genomics Verifi® Screen

1) Less Failure

The Maternal Genomics™ Verifi® screen offers a lower failure rate compared to others on the market. Higher failure rates mean you have a higher chance of needing a riskier invasive procedure because your first non-invasive test failed.

2) More Reputable

We use the Verifi® sequencing screen developed by Illumina®, the company with the most scientifically published DNA sequencing technology in the world.

3) More Timely

 The Verifi® screen can be done as early as 10 weeks gestation – no other blood screening test has earlier timing – and your results are ready within 7 business days.

Test Failures May Lead to Invasive Procedures: Theoretical example of the number of invasive procedures requested due to NIPT failure and false positive rates of the assays. Failure rates include assay failures and samples rejected due to low fetal fraction.